INmune Bio Advances Alzheimer’s and Cancer Trials

Introduction to INmune Bio Inc.

INmune Bio Inc. (NASDAQ: INMB; Korean name: 인뮤네 바이오) is a clinical-stage biotechnology company headquartered in Boca Raton, Florida. The company develops therapies that engage the patient’s innate immune system, pursuing two core platforms: XPro1595, a soluble TNF inhibitor for neuroinflammation indications such as Alzheimer’s disease, and INKmune™, a priming agent for natural killer (NK) cells targeting residual cancer cells after initial treatments.

Corporate Structure

Founded in September 2015, INmune Bio employs between 11 and 50 people, with research, development, and corporate functions based in Boca Raton. Its executive team combines scientific and financial expertise:

• Raymond J. Tesi, MD, Chief Executive Officer, has experience in biotech leadership and transplant surgery, having founded Coronado Biosciences and served as CEO/CMO of FPRT Bio.
• David J. Moss, Chief Financial Officer, has been involved in financings and public listings since 1995 and holds an MBA from Rice University.
• Professor Mark Lowdell, PhD, CSO/CMO, is a translational immunotherapy expert at University College London and Director of Cellular Therapy at Royal Free London NHS Foundation Trust.
• Christopher J. Barnum, PhD, Vice President of Neuroscience, has worked in academia and industry, including at Emory University and Takeda Pharmaceuticals.
• Joshua S. Schoonover, Esq., General Counsel, focuses on intellectual property and transactional law, holding a JD from Western Sierra Law School.
• Tara Lehner, Vice President of Clinical Operations, manages global trial execution and site partnerships.

Biotechnology by National Cancer Institute

Recent Developments and News

On December 4, 2024, INmune Bio partnered with OmniScience to implement the Vivo genAI platform in its global Phase 2 Alzheimer’s trial (AD02), enabling real-time data integration from electronic data capture (EDC), clinical outcome assessments (COAs), and wearable devices. Early rollout identified data discrepancies, improved cohort visualization, and facilitated enrollment decisions.

On January 28, 2025, the first patient enrolled in the Phase II portion of a metastatic castration-resistant prostate cancer (mCRPC) trial received INKmune at the West Los Angeles VA Medical Center under Principal Investigator Matthew Rettig, MD. This outpatient trial arm evaluates safety and dosing of INKmune in up to 30 men with mCRPC.

In its March 27, 2025 business update, the company reported full enrollment of 208 patients in the blinded, randomized Phase 2 AD02 trial targeting early Alzheimer’s disease with biomarkers of neuroinflammation. Two interim analyses confirmed a strong correlation between the novel cognitive measure EMACC and the Clinical Dementia Rating–Sum of Boxes (p<0.001). The study also differentiated between prodromal (CDR 0.5) and mild dementia (CDR 1.0) patients (effect size d=0.87, p<0.0001). Additional highlights included a webinar on EMACC’s development, a publication in Cell Reports on soluble TNF’s role in remyelination, improvements in EEG biomarkers in moderate-to-severe Alzheimer’s disease patients, and observed changes in synaptic proteins after a 12-week treatment with XPro1595.

On June 30, 2025, INmune Bio filed a prospectus supplement (Form 424B5) to offer 3,000,000 shares at $6.30 each, aiming to raise $18.9 million gross and approximately $17.6 million net of placement agent fees. The shelf registration allows for up to $250 million in future offerings, with $162 million remaining available.

Financial and Strategic Analysis

As of June 30, 2025, INMB shares closed at $2.03, down 61.93% year-to-date, on a volume of 5,953,403 shares. Yahoo Finance data indicates:

• Market capitalization: $152.6 million (intraday)
• Trailing EPS: –1.93; net loss: $40.8 million (ttm)
• Total cash: $19.3 million; debt/equity ratio: 1.17%
• Levered free cash flow: –$18.2 million (ttm)

The $17.6 million net proceeds from the June 30 offering are expected to support ongoing clinical trials, biomarker development, and general operations. The remaining balance of the shelf registration provides strategic flexibility for additional financings.

Market Position and Industry Context

INmune Bio operates at the intersection of immunology, neurology, and oncology. The XPro1595 program addresses an emerging perspective of Alzheimer’s disease as driven by chronic neuroinflammation rather than solely by amyloid pathology. The AD02 trial’s focus on a biomarker-driven population and novel cognitive endpoints positions the company within a competitive field of neuroinflammation therapies. INKmune’s NK cell-priming mechanism targets minimal residual disease in cancer—a growing segment within immuno-oncology. The company’s dual-platform strategy differentiates it from firms focused exclusively on Alzheimer’s or oncology, while acknowledging the execution risks inherent to clinical-stage biotechs and the volatility in share performance.

tl;dr

• AD02 Phase 2 enrollment of 208 patients completed on September 27, 2024; top-line cognitive results are expected in Q2 2025.
• First Phase II mCRPC patient dosed with INKmune on January 28, 2025, at West LA VA Medical Center.
• Raised up to $18.9 million in a June 30, 2025 public offering, netting $17.6 million for trial support.
• Shares traded at $2.03 on June 30, 2025, with a market cap of $152.6 million; cash runway supported by recent financing.